Endometriosis UK believes that those with endometriosis should be able to choose the most appropriate management and treatment options for them. There are far too few options available due to the historic lack of research into endometriosis, and we are pleased to see NICE approving this new medication for endometriosis.
Endometriosis UK welcomes the approval of Linzagolix (Yselty) for NHS use in England to treat symptoms of endometriosis in adults, along with hormonal add back therapy (ABT, commonly known as hormone replacement therapy), as an alternative where other medical or surgical treatment for endometriosis has been tried. We call on all other nations to approve this medication as an option available to all across the UK.
Linzagolix is a gonadotrophin releasing hormone (GnRH) antagonist and works by supressing oestrogen inducing a ‘medical menopause’, this medication will not be appropriate for all. It is similar to the GnRH antagonist Relugolix which was approved by NICE in March, however unlike Relugolix, Linzagolix does not contain add-back hormonal therapy which is to be taken separately. As with all menopause inducing medication, it is recommended that bone density is monitored.
Endometriosis UK calls for more investment in research to find better management and treatment options, the cause, and one day a cure.
